4Small JG, Hirsch SR, Arvantis LA, et al. Quetiapine in patients with schizophrenia : A high and low - dose - double - blind comparison with placebo [J]. Arch Gen Psychiatry, 1997,54(6):549 - 553.
5Mullen J ,Jibson MD, Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiepine and risperidon in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability study [J]. Clin Ther,2001,23(11) :1839- 1854.
6Blin O,Mieallef J. Antipsychotic- associated weight gain and clinical outcome parameters[J]. J Clin Psychiatry, 2001,62 Suppl 7:11.
7Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia[J]. J Clin Endocrinol Metab, 2001,86 (5) :1930 - 1935.
3Ebinc H,Ozkurt ZN,Ebinc FA,et al.Effects of sympatholytic ther-apy with moxonidine on serum adiponectin levels in hypertensivewomen[J].J Int Med Res,2008,36(1):80-87.
4Piecha G,Adamczak M,Chudek J,et al.Indapamide decreasesplasma adiponectin concentration in patients with essential hyper-tension[J].Kidney Blood Press Res,2007,30(3):187-194.
5Kobayashi S,Satoh M,Namikoshi T,et al.Blockade of serotonin2A receptor improves glomerular endothelial function in rats withstreptozotocin-induced diabetic nephropathy[J].Clin Exp Neph-rol,2008,12(2):119-125.
6Ogawa S,Mori T,Nako K,et al.Reduced albuminuria with sarpog-relate is accompanied by a decrease in monocyte chemoattractantprotein-1 levels in type 2 diabetes[J].Clin J Am Soc Nephrol,2008,3(2):362-368.
7Miyazaki Y,Cersosimo E,Triplitt C,et al.Rosiglitazone decreasesalbuminuria in type 2 diabetic patients[J].Kidney Int,2007,72(11):1367-1373.
8Chiang CK,Ho TI,Peng YS,et al.Rosiglitazone in diabetes controlin hemodialysis patients with and without viral hepatitis infection:effectiveness and side effects[J].Diabetes Care,2007,30(1):3-7.
10Proctor SD,Kelly SE,Stanhope KL,et al.Synergistic effects of con-jugated linoleic acid and chromium picolinate improve vascularfunction and renal pathophysiology in the insulin-resistant JCR:LA-cp rat[J].Diabetes Obes Metab,2007,9(1):87-95.
